Nevasic used in a clinical trial by Manchester University
Nevasic has been through its first clinical trial with cancer patients, independently organised and managed by Manchester University.
The clinical trial was organised by Professor Alex Molassiotis, Professor of Cancer and Supportive Care at the University of Manchester as part of a research project linked to a student’s PhD study. Professor Molassiotis has now moved to an overseas position, but the students thesis papers have now been published.
The protocol for the trial was prepared by staff of the university and to maintain independence and impartiality DAVAL were not involved in this process or during the course of the trial. We supplied access to the Nevasic product on a free basis.
In a statement from Professor Alex Molassiotis – using N=99 – “Early indications from the ongoing analysis suggest that, while CINV levels are not significantly different among the assessed groups of patients, there may be less use of ‘as required’ rescue antiemetics after the chemotherapy in the Nevasic group (27.9% in Nevasic group, 32.8% in music control group and 51.5% in the standard care control group), and there may be a non-significant trend for a better global health-related quality of life in the Nevasic group (P=0.06)”.
Access to the full published report:
When you reach the page hosting the abstract information at the Manchester.ac.uk site – you will see a link which you can use to download the full published paper.
The most relevant pages are 174 – 214 of a 350 page document.
While we regard the trial as successful – we are now actively seeking more research organisations to run more trials.